Investors double down on AI drug development
Funding for artificial intelligence (AI) in drug development hit $4.1 billion in 2021, a 36% increase from the year before, according to Emersion Insights. The AI drug development industry has gained a lot of attention from investors, venture capital firms, and corporate investment funds in recent years. Read More
Resilience key to success during pandemic and beyond
It has been a challenging past couple of years for the world with the pandemic impacting seemingly every aspect of life. Companies that have remained agile and dedicated to problem-solving have been able to weather the storm more easily compared to those that lacked strong contingency plans, according to Bryan Katz, senior vice president and global head of solution development at Syneos Health, who moderated a panel discussion at Biotech Showcase 2022. Read More
Developments in cell therapy boost potential for autoimmune disease treatments
Healthcare leaders are working together to change the therapeutic landscape for autoimmune diseases, which are often due to unknown causes, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Atara Biotherapeutics, Kyverna Therapeutics, and the National Institutes of Health are a few organizations that are dedicated to finding treatments for patients with limited options. Read More
Do advanced therapies have a place in women's health?
Change may be on the horizon for the traditionally competitive and underinvested field of women's health, according to scientific experts in the field. With increased awareness, fast-paced innovation, and appropriate investment, the sector is ripe for progress. ScienceBoard spoke with Martin Lehr, CEO of Context Therapeutics, as part of Biotech Finance Month 2022. Read More
How biotech startups can secure funding, according to investors
What are strategies that emerging biotech companies can use to attract investors and secure funding that supports the development of their programs and technology? A panel of investors and finance professionals discussed the challenges and opportunities during the virtual Biotech Showcase 2022 event in a session titled "Early Seed Financing." Read More
ARM update points to strong 2022 for cell and gene therapy industry
Despite a turbulent investment year, the cell and gene therapy space continued to innovate and develop at an extraordinary speed, according to the "Cell & Gene State of the Industry Briefing," which was delivered on January 11 by the Alliance for Regenerative Medicine (ARM) in partnership with Biotech Showcase. Read More
How COVID-19 has shed light on importance of biotech tools, health equity
As the world enters the third year of the COVID-19 pandemic, it is clear that the virus has taught humanity some very tough lessons, but there have also been significant scientific advances. A panel explored the current challenges facing the industry, along with the silver linings, on January 10 at Biotech Showcase 2022. Read More
Rare disease treatments continue to advance alongside gene therapies
Rare diseases represent an underserved and frequently overlooked area in healthcare. As a result, funding for research in these diseases is often limited. However, many of these diseases are fatal or highly impair a patient's quality of life. According to a recent report from Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard, some institutions are focusing their efforts in the area of rare diseases. Read More
Gene therapy research collaborations gain traction for next-gen medicines
Research collaborations are becoming increasingly more common, allowing companies to pool existing resources to advance innovations in the field of medicine. There are many partnerships within the gene therapy field, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Some companies engaging in such research collaborations are Regeneron, EdiGene, and Ferring Ventures. Read More
FDA authorizes Pfizer's COVID-19 pill
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for nirmatrelvir and ritonavir tablets (which are co-packaged for oral use and sold under the brand name Paxlovid) for the treatment of mild to moderate COVID-19 in adults and pediatric patients (age 12 and older) who have tested positive for SARS-CoV-2 and who are at high risk of developing severe COVID-19, including hospitalization or death. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
